HeartBeam Loses its Chief Business Officer

HeartBeam Inc. President Robert Eno has taken on the duties and responsibilities of Executive Vice President and Chief Business Officer Jon Hunt, Ph.D., who stepped down from his position and is now a strategic advisor and consultant for the company.
 
During his tenure with HeartBeam, Hunt made significant contributions to its business efforts, leading numerous initiatives and introductions with partner manufacturing and technology companies and health systems providers.

“Jon has made numerous critical contributions to HeartBeam by leading our planning efforts for market introductions of our products,” HeartBeam CEO/Founder Branislav Vajdic, Ph.D., said. “We understand his desire for a change of pace and a better work-life-balance, and we are excited that Jon will, as a key consultant, stay close to our strategic discussions and decisions. His dedication and commitment to HeartBeam have been greatly appreciated, and he will be missed in his current role. On behalf of the entire team at HeartBeam, we thank Jon for his outstanding service and leadership, and look forward to his expertise and insights in a consultancy role.”
 
As a consultant, Hunt will remain involved in the company’s business strategy and outreach to the medical community and sharing his wealth of knowledge and experience to help guide HeartBeam’s commercialization. His expertise and insights from more than 34 years’ experience in the medical device industry will continue to support the product launch timeline for the HeartBeam AIMIGo 12-Lead 3D vector electrocardiogram (VECG) Device and HeartBeam AIMI system.
 
“It has been a privilege to serve as CBO of HeartBeam, and I am incredibly proud of the rapid pace of our product timeline and our team’s ability to scale our commercialization path. After almost four decades in the cardiovascular medical device industry, I want to spend more time focusing on my family in the U.K. and U.S,” Hunt stated. “I look forward to continuing to work with the team as a consultant, focusing on business strategy as the company brings this breakthrough technology to market for high-risk cardiac patients.”
 
HeartBeam Inc. is a cardiac technology company that developed the first and only 3D-vector ECG platform for heart attack detection. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (FDA) for marketing in the United States or other geographies. 

Read more: HeartBeam Acquires LIVMOR Assets